Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN84,3584,380,39
Msft1,58
Nokia4,3894,48-0,27
IBM1,50
Mercedes-Benz Group AG50,1950,21-1,01
PFE0,24
04.07.2025 18:00:42
Indexy online
AD Index online
select
AD Index online
 

  • 03.07.2025 23:00:00
Puma (NASDAQ Cons)
Závěr k 3.7.2025 Změna (%) Změna (USD) Objem obchodů (ks)
3,58 0,56 0,02 127 438
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 06.07.2025
Popis společnosti
Obecné informace
Název společnostiPuma Biotechnology Inc
TickerPBYI
Kmenové akcie:Ordinary Shares
RICPBYI.O
ISINUS74587V1070
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.12.2024 172
Akcie v oběhu k 05.05.2025 49 638 093
MěnaUSD
Kontaktní informace
Ulice10880 Wilshire Blvd., Suite 2150
MěstoLOS ANGELES
PSČ90024
ZeměUnited States
Kontatní osobaMariann Ohanesian
Funkce kontaktní osobyInvestor Relations
Telefon14 242 486 500
Fax14242486501
Kontatní telefon14 242 486 500

Business Summary: Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
Financial Summary: BRIEF: For the three months ended 31 March 2025, Puma Biotechnology Inc revenues increased 5% to $46M. Net income totaled $3M vs. loss of $4.8M. Revenues reflect Product Revenue, net increase of 7% to $43.1M. Net Income reflects Development and commercialization of innovative products segment income totaling $4M vs. loss of $2.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.10 to $0.06.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 06.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, President, Chief Executive Officer, SecretaryAlan Auerbach55
Chief Financial OfficerMaximo Nougues5605.11.201805.11.2018
Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance, and Law OfficerDouglas Hunt60